IB-T101 Injection for Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma

Launched by GRIT BIOTECHNOLOGY · Feb 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called IB-T101 for adults with advanced clear cell renal cell carcinoma, which is a type of kidney cancer. The trial aims to assess how safe and effective this treatment is, as well as how the body processes the drug. It is currently open for enrollment, meaning that they are looking for participants who are willing to join the study.

To be eligible, participants must be at least 18 years old and able to provide informed consent, meaning they understand the study and agree to take part. They should also have a good level of health with a specific score that indicates they can carry out daily activities. However, people with certain health conditions, such as significant brain issues or severe immune system problems, cannot participate. Those who join can expect to receive the IB-T101 injection and will be monitored for any side effects and how well the treatment is working. This is an important step in finding new therapies for kidney cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol;
• • 2. Age ≥18 years old;
• • 3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
• • 4. Expected survival time of ≥ 3 months;
• Exclusion Criteria:
• • 1. CNS dysfunction with clinical significance. For example, seizures, cerebral ischemia/hemorrhage, dementia, cerebellar diseases, cerebral edema, reversible posterior encephalopathy syndrome, or any autoimmune disease involving the CNS.
• • 2. Any form of primary and acquired immunodeficiency (such as severe combined immunodeficiency). Known human immunodeficiency virus (HIV) positive subjects
• • 3. Have experienced myocardial infarction or unstable angina within the 6 months prior to screening
• • 4. Pleural effusion requiring drainage for symptom management within 28 days prior to screening